Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight

DelveInsight's 'Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034' report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Unlock key insights into the Age-related Macular Degeneration Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Age-related Macular Degeneration Market Size [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Age-related Macular Degeneration Market Report

* In January 2025:- Hoffmann-La Roche- The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
* In January 2025:- Ocular Therapeutics Inc .- A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration.
* In January 2025:- Stealth Bio Therapeutics Inc .:- The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug.
* In the year 2021, the total Age-related Macular Degeneration prevalent cases were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2034.
* The US accounted for approximately 17,282,569 Age-related Macular Degeneration prevalent cases in the year 2021.
* In EU-5 countries the highest number of Age-related Macular Degeneration prevalent cases was observed in Germany with 7,850,793 cases in the year 2021, followed by France.
* Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.
* In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.
* In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple number of folds by 2034.
* In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age group 50-59 years, 60-69 years, 70-79 years, and greater than or equal to 80 years respectively. As per the estimates by DelveInsight, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022-2034.
* In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50-59 years, 60-69 years, 70-79 years, and greater than or equal to 80 years in 2021.
* In the US, the total diagnosed cases of dry AMD by stages were approximately 10,499,160 cases for early and intermediate dry AMD and 1,166,573 cases for advanced (geographic atrophy associated with dry AMD) in 2021. As per the analysis, stage-wise cases are also expected to by 2034.
* In the US, the total geographic atrophy cases by visual impairment were 349,972; 583,287; and 233,315 cases for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2021.
* The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics , and others.
* Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101 , and others.

Stay ahead in the competitive landscape of the Age-related Macular Degeneration Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Age-related Macular Degeneration Treatment Market Size [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Epidemiology Insights in the 7MM

* Total Age-related Macular Degeneration Prevalent Cases
* Total Age-related Macular Degeneration Age-specific Cases
* Total Age-related Macular Degeneration Diagnosed Prevalent Cases
* Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
* Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
* Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Age-related Macular Degeneration epidemiology trends @ Age-related Macular Degeneration Prevalence [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Marketed Drugs

* Eylea (aflibercept): Regeneron Pharmaceuticals

Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye. At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.

* Beovu (brolucizumab): Novartis

Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics. Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.

* Lucentis (ranibizumab): Roche

Lucentis (ranibizumab) is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab. Ranibizumab is a humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing the binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2

Age-related Macular Degeneration Emerging Drugs

* OPT-302: Opthea Limited

OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. The company is currently conducting two concurrent Phase III clinical trials of OPT-302 for the treatment of wet AMD.

* KSI-301: Kodiak Sciences Inc.

KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.The drug is currently being evaluated in Phase III. The readouts of the trial are expected in quarter one of 2023.

* RGX-314: Regenxbio

RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. It is a potential one-time gene therapy for the treatment of wet AMD, diabetic retinopathy (DR) and other chronic retinal diseases.RGX-314 is currently being evaluated in patients with wAMD in Phase II and II/III clinical trials.

* Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

Danicopan (ALXN2040) is an oral drug developed by Alexion. It is an investigational first-in-class small-molecule inhibitor of factor D, an essential enzyme of the complement alternative pathway, which, when dysregulated, is implicated in the pathogenesis of AMD.The company is conducting a Phase II study in patients with GA secondary to AMD, and data is expected in 2023 plus.

* EG-301: Evergreen Therapeutics

EG-301 is an oral dosage form that is effective and safe in animal studies with fewer side effects and is used to treat patients over 50 years of age with dry macular disease. The company is currently conducting a Phase II study to treat non-exudative (dry) AMD.

Discover the future of Age-related Macular Degeneration Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Age-related Macular Degeneration Market Drivers and Barriers [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Market Outlook

Age-related Macular Degeneration (AMD) is a chronic, progressive, and severe disease of the central retina and is the main cause of irreversible blindness in the Western world and Asia-Pacific countries. Up to date, 8.7% of the worldwide population has AMD. The wet form of the disease is responsible for more than 90% of the severe central visual acuity (VA) loss associated with AMD. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function. In the past years, anti-VEGF injections have become the standard treatment for wet AMD, accounting for better results than the previous choices, such as photodynamic therapy (PDT) and laser photocoagulation. Currently, drugs like Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), work well to achieve a rapid resolution of exudative signs in most patients. Faricimab and Susvimo have also been recently approved for the treatment of Wet AMD.

Age-related Macular Degeneration Therapies and Companies

* Eylea (aflibercept): Regeneron Pharmaceuticals
* Beovu(brolucizumab): Novartis
* Lucentis (ranibizumab): Roche
* Vabysmo (faricimab): Roche
* Susvimo (ranibizumab): Roche

Explore the dynamics of the Age-related Macular Degeneration Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Age-related Macular Degeneration Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Age-related Macular Degeneration Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics , and others.
* Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
* Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Age-related Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders' Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-treatment-market-size-in-the-7mm-was-usd-9840-million-in-2023is-further-expected-to-grow-by-2034-delveinsight]
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market



This release was published on openPR.